Kochhar Rohit, Renehan Andrew G, Mullan Damian, Chakrabarty Bipasha, Saunders Mark P, Carrington Bernadette M
Department of Radiology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.
Institute of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Eur Radiol. 2017 Feb;27(2):607-617. doi: 10.1007/s00330-016-4337-z. Epub 2016 Apr 18.
To assess the use of MRI-determined tumour regression grading (TRG) in local response assessment and detection of salvageable early local relapse after chemoradiotherapy (CRT) in patients with anal squamous cell carcinoma (ASCC).
From a prospective database of patients with ASCC managed through a centralised multidisciplinary team, 74 patients who completed routine post-CRT 3- and 6-month MRIs (2009-2012) were reviewed. Two radiologists blinded to the outcomes consensus read and retrospectively assigned TRG scores [1 (complete response) to 5 (no response)] and related these to early local relapse (within 12 months) and disease-free survival (DFS).
Seven patients had early local relapse. TRG 1/2 scores at 3 and 6 months had a 100 % negative predictive value; TRG 4/5 scores at 6 months had a 100 % positive predictive value. All seven patients underwent salvage R0 resections. We identified a novel 'tram-track' sign on MRI in over half of patients, with an NPV for early local relapse of 83 % at 6 months. No imaging characteristic or TRG score independently prognosticated for late relapse or 3-year DFS.
Post-CRT 3- and 6-month MRI-determined TRG scores predicted salvageable R0 early local relapses in patients with ASCC, challenging current clinical guidelines.
• Post-chemoradiotherapy MRI (3 and 6 months) helps local response assessment in ASCC. • The MRI-TRG system can be used reproducibly in patients with ASCC. • The TRG system facilitates patient selection for examination under anaesthesia and biopsy. • The use of MRI-TRG predicts for detection of salvageable early local relapses. • The TRG system allows for a standardised follow-up pathway.
评估磁共振成像(MRI)确定的肿瘤消退分级(TRG)在肛管鳞状细胞癌(ASCC)患者放化疗(CRT)后局部反应评估及可挽救的早期局部复发检测中的应用。
回顾了一个通过集中多学科团队管理的ASCC患者前瞻性数据库中,74例完成CRT后3个月和6个月常规MRI检查(2009 - 2012年)的患者。两名对结果不知情的放射科医生进行共识解读,并回顾性地分配TRG评分[1(完全缓解)至5(无反应)],并将其与早期局部复发(12个月内)和无病生存期(DFS)相关联。
7例患者出现早期局部复发。3个月和6个月时TRG 1/2评分具有100%的阴性预测值;6个月时TRG 4/5评分具有100%的阳性预测值。所有7例患者均接受了挽救性R0切除。我们在超过一半的患者中发现了MRI上一种新的“电车轨道”征,6个月时早期局部复发的阴性预测值为83%。没有影像学特征或TRG评分能独立预测晚期复发或3年DFS。
CRT后3个月和6个月MRI确定的TRG评分可预测ASCC患者可挽救的R0早期局部复发,对当前临床指南提出了挑战。
• 放化疗后MRI(3个月和6个月)有助于ASCC的局部反应评估。• MRI - TRG系统可在ASCC患者中重复使用。• TRG系统有助于选择患者进行麻醉下检查和活检。• MRI - TRG的应用可预测可挽救的早期局部复发的检测。• TRG系统允许标准化的随访路径。